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Abstract: Deficiency in cytochrome P450 (CYP) 7B1, also known as oxysterol 7α-hydroxylase, in
humans leads to hereditary spastic paraplegia type 5 (SPG5) and in some cases in infants to liver
disease. SPG5 is medically characterized by loss of motor neurons in the corticospinal tract. In an effort
to gain a better understanding of the fundamental biochemistry of this disorder, we have extended
our previous profiling of the oxysterol content of brain and plasma of Cyp7b1 knockout (-/-) mice to
include, amongst other sterols, 25-hydroxylated cholesterol metabolites. Although brain cholesterol
levels do not differ between wild-type (wt) and knockout mice, we find, using a charge-tagging
methodology in combination with liquid chromatography–mass spectrometry (LC–MS) and multistage
fragmentation (MSn), that there is a build-up of the CYP7B1 substrate 25-hydroxycholesterol (25-HC) in
Cyp7b1-/- mouse brain and plasma. As reported earlier, levels of (25R)26-hydroxycholesterol (26-HC),
3β-hydroxycholest-5-en-(25R)26-oic acid and 24S,25-epoxycholesterol (24S,25-EC) are similarly
elevated in brain and plasma. Side-chain oxysterols including 25-HC, 26-HC and 24S,25-EC are known
to bind to INSIG (insulin-induced gene) and inhibit the processing of SREBP-2 (sterol regulatory
element-binding protein-2) to its active form as a master regulator of cholesterol biosynthesis. We
suggest the concentration of cholesterol in brain of the Cyp7b1-/- mouse is maintained by balancing
reduced metabolism, as a consequence of a loss in CYP7B1, with reduced biosynthesis. The Cyp7b1-/-
mouse does not show a motor defect; whether the defect in humans is a consequence of less efficient
homeostasis of cholesterol in brain has yet to be uncovered.
Keywords: cytochrome P450; CYP7B1; hereditary spastic paraplegia; SPG5; 25-hydroxycholesterol;
7α,25-dihydroxycholesterol; cholestenoic acid; cholesterol; liquid chromatography–mass
spectrometry; multistage fragmentation
1. Introduction
Cytochrome P450 (CYP) 7B1 (cytochrome P450 family 7 subfamily B member 1) was first identified
in 1995 and found to be primarily expressed in brain in rodents [1]. CYP7B1 is an oxysterol- and
steroid- 7α-hydroxylase, accepting many oxysterols and cholestenoic acids as substrates as well as
steroids including dehydroepiandrosterone (DHEA) [2–4]. In humans, deficiency in the enzyme was
Biomolecules 2019, 9, 149; doi:10.3390/biom9040149 www.mdpi.com/journal/biomolecules
Biomolecules 2019, 9, 149 2 of 22
first revealed in a ten-week-old boy presenting with severe liver disease [5]. In more recent studies,
treatment of another infant with this enzyme deficiency with chenodeoxycholic acid has proved
successful in resolving liver disease [6]. CYP7B1 is expressed in human hippocampus and interestingly
CYP7B1 mRNA is significantly reduced in dentate neurons from Alzheimer’s disease subjects [7].
In mice, deletion of Cyp7b1 results in a mild phenotype despite elevation of tissue and plasma
levels of its oxysterol substrates 25-hydroxycholesterol (25-HC) and 26-hydroxycholesterol, presumably
the 25R-epimer, (26-HC, also known as 27-hydroxycholesterol, see Supplementary Materials, Table S1
for abbreviations, common and systematic names) [8]. In light of this mouse data, it was surprising
when Tsaousidou et al. found in 2008 that sequence alterations in CYP7B1 were associated with
hereditary spastic paraplegia type 5 (SPG5) in humans [9]. Subsequent studies have confirmed patients
suffering from SPG5 have a metabolic phenotype characteristic of inactive CYP7B1 [10–13].
In an effort to understand the differences between mouse and human with respect to defective
CYP7B1, we embarked on a sterolomic investigation of mouse brain and plasma exploiting
enzyme-assisted derivatization for sterol analysis (EADSA) and liquid chromatography–mass
spectrometry (LC–MS) with multistage fragmentation (MSn). We previously found that in Cyp7b1
knockout (Cyp7b1-/-) mouse brain the concentration of cholesterol was similar to that of the
wild-type (wt, Cyp7b1+/+), as were the levels of 24S-hydroxycholesterol (24S-HC) [14]. On the other
hand, concentrations of (25R)26-hydroxycholesterol (26-HC), 3β-hydroxycholest-5-en-(25R)26-oic
acid (3β-HCA) and 24S,25-epoxycholesterol (24S,25-EC) were elevated, presumably being
CYP7B1 substrates [12,14]. Now, delving deeper into the sterolome, we reveal that 25-HC
and 26-hydroxydesmosterol (26-HD) are also elevated in Cyp7b1-/- mouse brain, whereas
7α,25-dihydroxysterols are reduced in abundance, but other oxysterols 24R-hydroxycholesterol
(24R-HC), 7α- and 7β-hydroxycholesterol (7α-HC, 7β-HC) do not change in concentration between
the two genotypes. We suggest that elevated levels of 25-HC, 26-HC and 24S,25-EC in brain reduce the
expression of cholesterol biosynthetic genes by inhibiting the processing of SREBP-2 (sterol regulatory
element-binding protein 2) to its active form as a master transcription for the mevalonate pathway [15],
thereby reducing cholesterol synthesis and compensating for its reduced metabolism (via the CYP7B1
pathway), thus maintaining cholesterol levels in Cyp7b1-/- mouse brain at wild-type levels. 25-HC,
24S,25-HC, 3β-HCA, and in some studies 26-HC, have all been found to be ligands to the liver X
receptors (LXRα, NR1H3; LXRβ, NR1H2) [16–18], activation of which increases the expression of
ATP-binding cassette transporter A1 (ABCA1) and apolipoprotein E (APOE), transporter and carrier
proteins important for maintaining correct sterol levels in neurons [19] and avoiding overload by
potentially toxic oxysterols.
2. Materials and Methods
2.1. Animals
Brain and plasma samples were from male mice of 13 and 23 months of age. Cyp7b1-/- and
Cyp7b1+/+ mice were littermates generated from Cyp7b1+/- crosses at the University of Edinburgh
animal facilities [3]. All mice were housed under standard conditions (7:00 am to 7:00 pm light/dark
cycle, 21 ◦C) with food and water available ad libitum. Tissue sampling was performed under the aegis
of the UK Scientific Procedures (Animals) Act, 1986, amended in 2012 to comply with the European
Directive 2010/63/EU. The study was conducted under PPL No.70/7870 with prior approval from the
University of Edinburgh Animal Welfare and Ethical Review Body. All mice were sacrificed in the
morning by cervical dislocation, trunk blood collected and brains removed, frozen on powdered dry
ice and stored at −80 ◦C.
2.2. Sample Preparation
Sterols including oxysterols were extracted from brain as described in [12,14,20,21]. In brief, mouse
brain was homogenised in ethanol containing isotope-labelled internal standards and oxysterol- and
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cholesterol-rich fractions separated by solid phase extraction (SPE) on a reversed phase C18 column. The
oxysterol-rich fraction was then divided into two aliquots (a and b) and the first treated with cholesterol
oxidase enzyme from Streptomyces sp. to oxidise 3β-hydroxy-5-ene groups to 3-oxo-4-ene equivalents,
suitable for subsequent derivatisation with the Girard P (GP) reagent (i.e., fraction a). The second
aliquot of the oxysterol fraction was treated with GP reagent directly, in the absence of cholesterol
oxidase (i.e., fraction b). This allowed the differentiation of oxysterols with a native 3-oxo-4-ene
structure (fraction b) from those with a 3β-hydroxy-5-ene structure (i.e., (fraction a)–(fraction b)). The
cholesterol-rich fraction was treated separately, but in the same way as the oxysterol-rich fraction.
Plasma samples were prepared as described in Autio et al. and Crick et al. by extraction into
ethanol followed by SPE to separate cholesterol- and oxysterol-rich fractions [22,23]. The oxysterols
were then derivatised with GP reagent with (fraction a), or without (fraction b), prior oxidation by
cholesterol oxidase. For plasma analysis, two GP reagents were used [2H0]GP and [2H5]GP with either
fraction a or with fraction b, respectively. This allowed the duplex LC-MS analysis of oxysterol fractions
prepared with (fraction a) or without (fraction b) treatment with cholesterol oxidase (see Supplementary
Materials, Figure S1) [24].
2.3. Analysis
The oxidised/derivatised oxysterol-rich fractions were analysed by LC-MS (MSn) using an Ultimate
3000 LC system (Thermo Fisher Scientific, Loughborough, UK) and LTQ-Orbitrap mass spectrometer
(Thermo Fisher Scientific, Loughborough, UK) as described in Meljon et al. [20] and Crick et al. [23,24].
In brief, GP-derivatised oxysterols were separated on a reversed phase Hypersil Gold C18 column
(Thermo Fisher Scientific) using a methanol/acetonitrile/0.1% formic acid gradient. The eluent was
directed to an electrospray ionisation source (ESI) and analysed by high-resolution (60,000 at m/z 400)
MS and MS3 ([M]+→[M-Py]+→, where “-Py” corresponds to the loss of the pyridine group from the
molecular ion M+) scans performed in parallel in the Orbitrap and LTQ linear ion-trap, respectively.
Quantification was performed using the isotope dilution method.
3. Results
3.1. Brain
3.1.1. Oxysterols
We previously reported the levels of 24S-HC, 24S,25-EC [14], 26-HC, 3β-HCA and the combination
of 7α,26-dihydroxycholesterol (7α,26-diHC) and 7α,26-dihydroxycholest-4-en-3-one (7α,26-diHCO)
(i.e., fraction a, [12]) in Cyp7b1-/- and Cyp7b1+/+ mouse brain but, at that time, did not analyse
25-hydroxylated sterols or other 7α-hydroxylated sterols, or oxysterols derived from cholesterol
precursors. Here we report new data for these additional sterols. The complete data set is presented in
Figure 1 and Supplementary Materials, Table S1.
In the Cyp7b1+/+ mice, the concentration of 25-HC is below the limit of detection of the LC-MS
method (<0.01 ng/mg); however, in the Cyp7b1-/- mice, the level of 25-HC is significantly elevated
(p < 0.001) in both 13 (0.89 ± 0.14 ng/mg, mean ± SD) and 23 (2.09 ± 0.45 ng/mg) month-old mice. This
is particularly evident when using an extended chromatographic gradient (33 min) which resolves
25-HC from other side-chain hydroxycholesterols (Figure 2). Unlike 24S-HC, 24R-HC is only a minor
oxysterol in mouse brain [21], but like 24S-HC its concentration in the Cyp7b1-/- mouse brain was not
found to differ from that measured in wild-type (wt) animals (0.20 ± 0.09 ng/mg and 0.30 ± 0.03 ng/mg
at 13 and 23 months, respectively, in wt).
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acid (3β,7α-diHCA) and 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic acid (7αH,3O-CA) is from [12]. At 
13 months of age, n = 3 animals, and at 23 months of age, n = 4 animals, for each genotype. Student’s 
t-tests were performed between wild-type (wt) and Cyp7b1-/- animals of the same age and significance 
indicated by *, p < 0.05; **, p < 0.01; ***, p < 0.001 placed above the appropriate bars for the transgenic 
animals. Error bars represent standard deviation (SD). 7α,26-diHC was measured in combination 
with 7α,26-diHCO. The combined value is applied to the 7α,26-diHCO label only. Similarly, 7α,25-
diHC was measured in combination with 7α,25-diHCO. The combined value is applied to the 7α,25-
diHCO label only. The 7α,25-dihydroxysterols were incompletely resolved from 7α,24-
dihydroxysterols, thus the value given includes values from both dihyroxysterols. 24S,25-EC becomes 
hydrolysed to 24,25-dihydroxycholesterol (24,25-diHC), undergoes methanolysis to 24-hydroxy,25-
methoxycholesterol (24H,25OMe-C) and isomerisation to 24-oxocholesterol (24-OC) during sample 
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Figure 1. Concentrations of oxysterols in mouse brain. To maintain data to a single y-axis, a magnification
factor of 0.1 has been applied to 24S-HC. Data for 24S-HC and total 24S,25-EC is from [14] and for 26-HC,
3β-HCA, 7α,26-diHC + 7α,26-diHCO, 3β,7α-dihydroxycholest-5-en-(25R)26-oic acid (3β,7α-diHCA)
and 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic acid (7αH,3O-CA) is from [12]. At 13 months of age,
n = 3 animals, and at 23 months of age, n = 4 animals, for each genotype. Student’s t-tests were
performed between wild-type (wt) and Cyp7b1-/- animals of the same age and significance indicated
by *, p < 0.05; **, p < 0.01; ***, p < 0.001 placed above the appropriate bars for the transgenic
animals. Error bars represent stan ard deviation (SD). 7α,26-diHC was measured in combination with
7α,26-diHCO. The combined value is applied to the 7α,26-diHCO label only. Similarly, 7α,25-diHC
was measured in combination with 7α,25-diHCO. The combined value is applied to the 7α,25-diHCO
label only. The 7α,25-dihydroxysterols were incompletely resolved from 7α,24-dihydroxysterols,
thus the value given includes values from both dihyroxysterols. 24S,25-EC becomes hydrolysed to
24,25-dihydroxycholesterol (24,25-diHC), undergoes methanolysis to 24-hydroxy,25-methoxycholesterol
(24H,25OMe-C) a d isomerisati to 24-oxocholesterol (24-OC) during sample preparation. The total
24S,25-EC value is the sum of remaining 24S,25-EC and th s three secondary forms.
As reported earlier [12], the concentration of 26-HC is elevated in the Cyp7b1-/- mice (Figure 2a,b).
This oxysterol is formed by oxidation of cholesterol by CYP27A1 (cytochrome P450 family 27 subfamily
A member 1) [25]. CYP27A1 can also oxidize desmosterol (24-DHC, 24-dehydrocholesterol) to
26-HD [26] and its cis (Z) and trans (E) geometric isomers have been reported to be present in
newborn mouse brain [20]. Although only minor oxysterols, both isomers are found to be elevated
in concentration in Cyp7b1-/- mouse brain, most prominently in 23-month-old animals, where the
concentration of the (E) isomer was raised from 0.01± 0.00 ng/mg in e wt to 0.04 ± 0.00 ng/mg in the
Cyp7b1-/- animals (p < 0.001, Figures 1 and 3).
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Figure 2. LC-MS(MSn) analysis of monohydroxycholesterols in mouse brain. Reconstructed ion-
chromatograms (RICs) from analysis of Cyp7b1-/- (upper panel) and Cyp7b1+/+ (wt, lower panel) 23-
month-old animals generated from (a) 17 min and (b) 33 min chromatographic gradients. (c) Multiple 
reaction monitoring (MRM) chromatogram (m/z 534.4455.4353.3, see Supplementary Materials, 
Figure S2) from Cyp7b1-/- (upper panel) and Cyp7b1+/+ (lower panel) animals generated from the 33 
min chromatographic gradient. Magnification factors in chromatograms (a–c) are as indicated. 
Concentration of the analyte indicated by retention time is given in the right-hand corner of the 
chromatograms. MS3 spectra ([M]+[M-Py]+) of (d) 24S-HC from a Cyp7b1+/+ mouse and of (e) 24R-
HC, (f) 25-HC, (g) 26-HC and (h) 7β-HC and 7α-HC, from a Cyp7b1-/- mouse. Many GP-derivatised 
sterols give syn and anti conformers which may or may not be chromatographically resolved. Generic 
fragmentation schemes are illustrated in Supplementary Materials, Figures S3 and S4. 
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Figure 2. LC-MS(MSn) analysis of monohydroxycholesterols in mouse brain. Reconstructed
ion-chromatograms (RICs) from analysis of Cyp7b1-/- (upper panel) and Cyp7b1+/+ (wt, lower panel)
23-month-old animals generated from (a) 17 min and (b) 33 min chromatographic gradients. (c) Multiple
reaction monitoring (MRM) chromatogram (m/z 534.4→455.4→353.3, see Supplementary Materials,
Figure S2) from Cyp7b1-/- (upper panel) and Cyp7b1+/+ (lower panel) animals generated from the
33 min chromatographic gradient. Magnification factors in chromatograms (a–c) are as indicated.
Concentration of the analyte indicated by retention time is given in the right-hand corner of the
chromatograms. MS3 spectra ([M]+→[M-Py]+→) of (d) 24S-HC from a Cyp7b1+/+ mouse and
of (e) 24R-HC, (f) 25-HC, (g) 26-HC and (h) 7β-HC and 7α-HC, from a Cyp7b1-/- mouse. Many
GP-derivatised sterols give syn and anti conformers which may or may not be chromatographically
resolved. Generic fragmentation schemes are illustrated in Supplementary Materials, Figures S3 and S4.
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7α-HC is also a minor oxysterol in wt mouse brain (0.01 ng/mg), but in brain from the Cyp7b1-/- 
23-month-old mice its concentration is raised to 0.02 ± 0.00 ng/mg (p < 0.05). Likewise, 7β-HC, another 
minor oxysterol, is more abundant in brain from the 23-month-old Cyp7b1-/- mice (0.03 ± 0.01 ng/mg) 
than the wt animals of the same age (0.02 ± 0.00 ng/mg, p < 0.05). 
7α,25-Dihydroxycholesterol (7α,25-diHC) and 7α,25-dihydroxycholest-4-en-3-one (7α,25-
diHCO) are present at low levels in brain (Figure 1). Using the EADSA methodology, these two 
dihydroxysterols can be measured in combination (fraction a) more accurately than for the 3β-
G:\X-CAL\...\Z-26-OHD_AM_110914_01 23/09/2011 16:55:04 1 pg/uL 60%MeOH, 0.1%FA
RT: 0.00 - 16.02
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Time (min)
0
10
20
30
40
50
60
70
80
90
1000
10
20
30
40
50
60
70
80
90
100
Re
lat
ive
 A
bu
nd
an
ce
NL: 6.94E3
m/z= 
532.3871-532.3925 F: 
FTMS + p ESI Full ms 
[400.00-605.00]  MS 
Z-26-
OHD_AM_110914_01
NL: 4.44E5
m/z= 
532.3871-532.3925 F: 
FTMS + p ESI Full ms 
[400.00-605.00]  MS 
e-26-
ohd_am_110914_001
0
%RA
0 2 4 6 8 10 12 14
3g
16
min
100
RIC: 532.3898 ± 5 ppm
100
0
%RA
26-HD(E)
26-HD(Z)
7.11
7.46
26-HD(Z)
26-HD(E)
 
I:\Anna\...\AM_KO_680_120707_03 19/07/2012 21:57:11
0.3 pg/ul Fr1a/Fr1+2(60%MeOH, 0.1%FA)
AM_KO_680_120707_03 #1316 RT: 7.75 AV: 1 NL: 1.28E4
F: ITMS + c ESI Full ms3 532.39@cid30.00 453.35@cid35.00 [120.00-550.00]
140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Re
lat
ive
 A
bu
nd
an
ce
150 200 250 300 350 400 450
m/z
151
10
0
%RA
MS3: 532453
7.75 min (Cyp7b1-/-)
24-OC 425
3h
410
177 435325
*b2
M-Py-18
M-Py-28
‘*e
353
‘*f
163
*b3-28
*b1-12
367
‘*g
[M]+
381
‘*h
 
Figure 3. LC-MS(MSn) analysis of monohydroxydesmosterols and their isomers 24S,25-EC and 24-OC
in mouse brain. (a) RICs from analysis of Cyp7b1-/- (upper panel) and Cyp7b1+/+ (wt, lower panel)
23-month-old animals generated from the 17 min gradient. (b) Total ion chromatograms (TICs) for
the MS3 transition [M]+→[M-Py]+→ using the same gradient as in (a). Concentration of the analyte
indicated by retention time is given in the right-hand corner of the chromatograms. MS3 spectra
([M]+→[M-Py]+→) of (c) 24S,25-EC, (d) 26-HD(Z), (e) 26-HD(E) and (h) 24-OC from the Cyp7b1-/-
mouse; and of authentic and of standards of (f) 26-HD(Z) and 26-HD(E) with their (g) chromatograms.
24-OC is derived from 24S,25-EC during the sample preparation process. Many GP-derivatised sterols
give syn and anti conformers which may or may not be chromatographically resolved.
7α-HC is also a minor oxysterol in wt mouse brain (0.01 ng/mg), but in brain from the Cyp7b1-/-
23-month-old mice its concentra ion is raised to 0.02 ± 0.0 ng/mg (p < 0.05). Likewise, 7β-HC, another
minor oxysterol, is more abundant in brain from the 23-month-old Cyp7b1-/- mice (0.03 ± 0.01 g/mg)
than the wt animals of the same age (0.02 ± 0.00 ng/mg, p < 0.05).
7α,25-Dihydroxycholesterol (7α,25-diHC) a d 7α,25-dihydroxycholest-4-en-3-one (7α,25-diHCO)
are present at low levels in brain (Figure 1). Using the EADSA met o ology, these two dihydroxysterols
can be measured in combination (fraction a) more accurately than for the 3β-hydroxy or 3-oxo analytes
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alone (fraction a–fraction b and fraction b, respectively). This is also true for 7α,26-diHC and
7α,26-diHCO [21]. 7α,25-diHC/7α,25-diHCO, like many other GP-derivatised oxysterols elute as
syn and anti conformers giving a pair of peaks. Unfortunately, the first of these peaks co-elutes
with the first peak from the 7α,24-dihydroxysterols, 7α,24-dihydroxycholesterol (7α,24-diHC)/
7α,24-dihydroxycholest-4-en-3-one (7α,24-diHCO), although the second peaks from 7α,25- and
7α,24-dihydroxysterols are resolved (Figure 4). However, as the first peaks are dominant, we decided to
measure concentrations of 7α25- and 7α,24-sterols in combination. In Cyp7b1-/- mouse brain, we found
that at both 13 and 23 months of age the concentration of the 7α,24/25-dihydroxysterols is reduced from
0.01± 0.00 ng/mg and 0.02 ± 0.00 ng/mg in the wt to 0.00 ± 0.00 ng/mg and 0.01 ± 0.00 ng/mg, in the
Cyp7b1-/- animals. Surprisingly, in our earlier study, we did not find that the 7α,26-dihydroxysterol
concentrations varied with genotype [12].
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Figure 4. LC-MS(MSn) analysis of dihydroxysterols in mouse brain. (a) RICs from analysis of
Cyp7b1-/- (upper panel) and Cyp7b1+/+ (wt, lower panel) 23-month-old animals, generated from
the 17 min gradient. (b) TICs for the MS3 transitions [M]+→[M-Py]+→ using the same gradient
as in (a). Concentratio of the analyte indicated by retention time is given in the rig t-hand
corner f the chromatograms. MS3 spectra ([M]+→[M-Py]+→) of (c) 24,25-diHC Cyp7b1-/- mouse;
and (d) 7α,24-diHC/7α,24-diHCO, (e) 7α,25-diHC/7α,25-diHCO, (f) unresolved mixture of 7α,24-
and 7α,25-dihydroxysterols, and (g) 7α,26-diHC/7α,26-diHCO from the Cyp7b1+/+ mouse and
(h) 24S,26-diHC from the Cyp7b1-/- mouse. 24,25-diHC is the hydrolysis product of 24S,25-EC.
24S,26-diHC was detected but not quantified. Many GP-derivatised sterols give syn and anti conformers
which may or may not be chromatographically resolved.
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The biochemical results presented above reveal an increased concentration of oxysterol ligands
to the LXRs and to INSIG (insulin-induced gene) in brain of the Cyp7b1-/- mouse. The biological
consequence of this is likely to be increased transport of cholesterol between cells through enhanced
expression of ABC transporters and APOE [27], and of reduced cholesterol biosynthesis via inhibition
of the SREBP-2 pathway [15].
3.1.2. Sterols
We have previously reported that the concentration of cholesterol in brain does not vary between
the Cyp7b1+/+ and Cyp7b1-/- genotypes (10.60 ± 1.43 ng/mg at 13 months old and 15.81 ± 0.65 at
23 months old in wt animals) [14]. Measurements of cholesterol precursors is limited in the current
LC-MS setting by the dynamic range of the chromatographic system, where injection of sufficient
sample to achieve peak areas of the necessary size to allow accurate measurements of cholesterol
precursors overloads the LC column with cholesterol. As the goal of the current study was primarily
to measure oxysterols, we only measured cholesterol precursors in a single brain of each genotype
from 13-month-old animals. Interestingly, the levels of both desmosterol and 8(9)-dehydrocholesterol
(8-DHC), an enzymatically derived isomer of 7-dehydrocholesterol (7-DHC), are reduced in the
Cyp7b1/-/- mouse (Figure 5).
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Figure 5. LC-MS(MSn) analysis of cholesterol and its precursors in mouse brain. RICs from analysis of
Cyp7b1-/- (upper panel) and Cyp7b1+/+ (wt, lower panel) 13-month-old animals, generated from the
17 min gradient. (a) RICs for cholesterol. (b) RICs for desmosterol (24-DHC) and 8-DHC. Concentration
of the analyte indicated by retention time is given in the right-hand corner of the chromatograms. MS3
spectra ([M]+→[M-Py]+→) of (c) cholesterol, (d) desmosterol and (e) 8-DHC from the Cyp7b1+/+ mouse.
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Although cholesterol levels do not differ between the two genotypes, the reduction of cholesterol
precursors in Cyp7b1-/- mouse brain does suggest a reduced cholesterol synthesis as a result of
oxysterol-induced inhibition of the SREBP-2 pathway.
3.2. Plasma
We have previously reported the concentrations of 26-HC and its downstream metabolites,
7α,26-diHC/7α,26-diHCO, 3β-HCA and 7αH,3O-CA in plasma [12]. Here, we extend that study
by reporting concentrations of further oxysterols, including 24S,25-EC, 25-HC and other 7-oxidised
metabolites (Figure 6 and Supplementary Materials, Table S1).
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Figure 6. Concentrations of oxysterols in mouse plasma. To maintain data to a single y-axis,
a magnification factor of 0.1 has been applied to 25-HC, 26-HC and 7αH,3O-CA. Data for 26-HC,
3β-HCA, 7α,26-diHCO, 3β,7α-diHCA and 7αH,3O-CA is from [12]. At 13 months of age, n = 5
animals, and at 23 months of age, n = 4 animals, for each genotype (for metabolites indicated by
abbreviations in italics, data was obtained from only one or two animals). Student’s t-tests were
performed between Cyp7b1+/+ (wt) and Cyp7b1-/- animals of the same age and significance indicated
by *, p < 0.05; **, p < 0.01; ***, p < 0.001 placed above the appropriate bars for the transgenic animals.
Error bars represent standard deviation (SD). 24S,25-EC becomes hydrolysed to 24,25-diHC, undergoes
methanolysis to 24H,25OMe-C and isomerisation to 24-OC during sample preparation. The total
24S,25-EC value is the sum of remaining 24S,25-EC and these three secondary forms.
As in brain, the concentration of total 24S,25-EC is significantly higher (p < 0.001) in plasma
of the Cyp7b1-/- mice (10.82 ± 2.74 ng/mL at 13 months, 8.63 ± 1.11 ng/mL at 23 months) than
Cyp7b1+/+ mice (1.16 ± 0.98 ng/mL at 13 months, 1.52 ± 0.59 ng/mL at 23 months, Supplementary
Materials, Figure S5). This is also true for 25-HC where the plasma concentration in the Cyp7b1-/- mice
(36.52 ± 7.04 ng/mL at 13 months, 42.19 ± 20.21 ng/mL at 23 months) is also higher (p < 0.001 at
13 months, p < 0.01 at 23 months) than in the Cyp7b1+/+ mice (0.74 ± 0.24 ng/mL at 13 months,
0.85 ± 0.26 ng/mL, Supplementary Materials, Figure S6). Unlike the situation for 24S,25-EC, 25-HC and
26-HC [12], where plasma concentrations are elevated in Cyp7b1-/- mice, the concentration of 24S-HC
does not vary between genotypes (in wt animals 2.02 ± 0.54 ng/mL at 13 months and 1.78 ± 0.58 ng/mL
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at 23 months). This is also true for the minor oxysterol 22R-hydroxycholesterol (22R-HC, in wt animals
0.17 ± 0.11 ng/mL at 13 months and 0.31 ± 0.21 ng/mL at 23 months).
CYP7A1 (cytochrome P450 family 7 subfamily A member 1) is the enzyme responsible for
the formation of 7α-HC from cholesterol [28]. The concentrations of 7α-HC and its metabolite
7α-hydroxycholest-4-en-3-one (7α-HCO) show considerable variation within each genotype at both ages
and no significant differences between genotypes are discernible. This is also true for 7-oxocholesterol
(7-OC), which may be formed from 7-DHC by CYP7A1 [29] and for 7β-hydroxycholesterol (7β-HC)
which can be formed from 7-OC by the enzyme HSD11B1 (hydroxysteroid 11β-dehydrogenase 1) [30].
An added complication is that each of these oxysterols may be formed from cholesterol via free radical
oxidation, perhaps during sample preparation or storage [31].
In plasma it was possible to differentiate the concentration of 7α,25-diHCO from that of 7α,25-diHC
which is essentially absent in mice of both genotypes. In the 13-month-old mice, 7α,25-diHCO was at
or below the detection limit in plasma from the Cyp7b1-/- animals but present in Cyp7b1+/+ plasma
(0.44 ± 0.30 ng/mL, p = 0.01, Supplementary Materials, Figure S7). 7α,26-diHCO was observed in
plasma from both genotypes at both ages, and at 13 months the concentration difference between
Cyp7b1+/+ (1.10 ± 0.44 ng/mL) and Cyp7b1-/- (0.64 ± 0.14 ng/mL) was almost significant p = 0.055).
At 13 months, the concentration of the downstream metabolite 7αH,3O-CA was almost significantly
different (p = 0.051, Supplementary Materials, Figure S8) between the wt (25.89 ± 10.91 ng/mL) and the
Cyp7b1-/- mice (14.21 ± 3.76 ng/mL) [12].
7α,12α-Dihydroxycholesterol (7α,12α-diHC) and 7α,12α-dihydroxycholest-4-en-3-one
(7α,12α-diHCO) are observed in plasma of both genotypes. There is also evidence for the presence of
12α-hydroxycholesterol (12α-HC).
7αH,3O-CA can be metabolized further to the CoA thioesters of
7α,24R-dihydroxy-3-oxocholest-4-en-(25R)26-oic and 7α-hydroxy-3,24-bisoxocholest-4-en(25R)26-oic
acid in the peroxisome [32,33]. The latter compound is unstable in our analytical system and
decomposes by loss of C-26 to give 7α-hydroxy-26-norcholest-4-en-3,24-dione (7αH,26-nor-C-3,24-diO)
which we observe in mouse plasma. An alternative route of metabolism of 7αH,3O-CA is
12α-hydroxylation in the endoplasmic reticulum by CYP8B1 (cytochrome P450 family 8 subfamily B
member 1) to give 7α,12α-dihydroxy-3-oxocholest-4-en-(25R)26-oic acid (7α,12α-diH,3O-CA) which
we also observe in plasma. Unfortunately, we do not have statistical data for 7αH,26-nor-C-3,24-diO or
7α,12α-diH,3O-CA as only one (or two) animals were analysed for each genotype at each age in this
study. This is also true for 12α-HC, 7α,12α-diHC and 7α,12α-diHCO.
Besides brain, Cyp7b1 is expressed in liver, lung, kidney and reproductive tract in mice [34]. Hence,
the origins of the quantitative differences observed in plasma between Cyp7b1-/- and Cyp7b1+/+ mice
are likely to be multifactorial. Nevertheless, the enhanced abundance of 25-HC, 26-HC, 24S,25-EC and
3β-HCA in Cyp7b1-/- mouse plasma confirms these molecules as substrates for CYP7B1. A decreased
abundance in 7α,26-diHCO and 7αH,3O-CA might also have been expected in the Cyp7b1-/- mouse;
however, these two metabolites can alternatively be synthesized via a pathway initiated by CYP7A1
which is elevated in the Cyp7b1-/- mouse [8].
4. Discussion
CYP7B1 is a known 7α-hydroxylase towards 25-HC, 26-HC and 3β-HCA [8,35]. CYP7B1 is
expressed in brain [1–3] and data presented here demonstrates its activity in mouse brain towards
25-HC, as seen by elevated levels of 25-HC and reduction in levels of its metabolite 7α,25-diHCO in
brain of the Cyp7b1-/- mouse. 26-HD exists as (Z) and (E) isomers and both are present at very low
levels in brain [20]; however, their elevated abundance in the Cyp7b1-/- mouse indicates that, like
26-HC, 26-HD(Z) and 26-HD(E) are substrates for CYP7B1 in brain.
The major route for cholesterol removal from brain is via oxidation by CYP46A1 to 24S-HC [36],
although other mechanisms also exist, most likely involving CYP27A1 and CYP7B1 [37,38]. CYP7B1 has
little activity towards 24S-HC, the product of CYP46A1 oxidation of cholesterol, where 7α-hydroxylation
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is catalysed by CYP39A1 (cytochrome P450 family 39 subfamily A member 1) [39]. By blocking one
of the pathways of cholesterol metabolism in brain by deletion of Cyp7b1, it may be predicted that
either cholesterol or 24S-HC levels would increase; however, neither of these events occurs. This can be
explained by down-regulation of cholesterol biosynthesis by inhibition of the SREBP-2 pathway. Besides
25-HC, 26-HC and 24S,25-EC are elevated in brain of the Cyp7b1-/- mouse. Each will interact with the
endoplasmic reticulum resident protein INSIG and block transport by SCAP (SREBP cleavage-activating
protein) of SREBP-2 to the Golgi for processing to its active form as the master transcription factor
for genes of the cholesterol biosynthesis pathway [15]. Although we do not prove this explanation
here, there is no reason to expect that the INSIG–SCAP–SREBP regulatory mechanism differs in cells
expressing or not expressing CYP7B1, other than with respect to the abundance of oxysterols and
steroids. 25-HC, 26-HC, 24S,25-EC and 3β-HCA are also ligands to the LXRs [16–18], both of which are
expressed in brain [40]. LXR target genes include Abca1, which codes for the cholesterol eﬄux pump
ABCA1, and Apoe which codes for the apolipoprotein APOE, which mediates transport of cholesterol
within the brain [19]. The lack of a major neurological phenotype in the Cyp7b1-/- mouse, despite
the absence of a key sterol metabolizing enzyme, is likely a consequence of the safety net provided
by side-chain oxysterols, INSIG–SCAP–SREBP and LXR working in concert to avoid detrimental
concentrations of cholesterol and of oxysterols building up in neuronal cells.
In humans, deficiency in CYP7B1 leads to SPG5, a form of spastic paraplegia, defined by
progressive neurodegeneration of corticospinal tract motor neurons. One hypothesis to explain the
different phenotype between CYP7B1-deficient mouse and human is that, in humans, oxysterol levels in
the central nervous system are less well regulated and reach a level toxic to corticospinal tract neurons
resulting in SPG5 [11]. In fact, Schöls et al showed that the concentration of total (the sum of esterified
and non-esterified) 26-HC in serum is correlated with SPG5 disease severity and duration [11]. They
found that at concentrations of 25-HC and 26-HC close to those found in serum of SPG5 patients,
both oxysterols were toxic towards motor neuron-like cells as well as cortical neurons derived from
human induced pluripotent stem cells (iPSCs) [11]. It should be noted that concentrations of these
molecules in serum from SPG5 patients (total 25-HC 177.9 ± 77.0 ng/mL, mean ± SD, n = 19; 26-HC
878.2 ± 207.1 ng/mL, n = 19) were far higher than the value measured for 26-HC in cerebrospinal fluid
(CSF, 12.9 ± 4.3 ng/mL, n = 19, concentration of 25-HC in CSF were not reported) and that the free
molecules (i.e., non-esterified oxysterols), which were used in toxicity tests, are likely to be present at
concentrations of about 10% of the sum of non-esterified and esterified molecules. 3β-HCA was also
found to be toxic to the cells but at concentrations higher than those found in SPG5 serum [11].
The concentrations of 25-HC, 26-HC and 3β-HCA (363.1 ± 82.1 ng/mL, n = 19) reported by Schöls
et al. in SPG5 serum [11] are considerably higher than those measured here in plasma for the Cyp7b1 -/-
mouse (25-HC, 36.52–42.19 ng/mL; 26-HC, 23.80–16.93 ng/mL; 3β-HCA, 7.32–6.69 ng/mL, numbers
are means at the two ages). However, we measured the concentrations of the free non-esterified
molecules, whereas Schöls et al. measured the total non-esterified plus esterified molecules [11].
A better comparison is provided by the data reported by Theofilopoulos et al., where the values for the
non-esterified molecules were measured as 25-HC 49.40 ± 11.38 ng/mL, 26-HC 97.75 ± 7.28 ng/mL and
368.40 ± 65.27 ng/mL, n = 9, in SPG5 plasma/serum [12]. The concentrations of non-esterified 26-HC
and 3β-HCA in human plasma/serum are considerably greater than those in the Cyp7b1-/- mouse, and
this may explain the presence of a motor neuron disease phenotype in SPG5 patients but not in the
Cyp7b1-/- mouse.
Theofilopoulos et al. also measured the concentration of 3β,7α-diHCA in human CSF and
plasma [12]. They found that in SPG5 patients the levels of this acid were significantly reduced
in both fluids compared to controls and, based on its neuroprotective effects towards oculomotor
neurons, suggested that its reduced levels in SPG5 patients may contribute towards their motor neuron
loss [12]. In the current study, we failed to detect 3β,7α-diHCA in either mouse brain or plasma. This is
probably a consequence of its greater rate of metabolism to 7αH,3O-CA by HSD3B7 (3β-hydroxysteroid
dehydrogenase type 7) in mice than in humans.
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CYP7B1 is an essential enzyme in the acidic pathway of bile acid biosynthesis [28,41]. Surprisingly,
this is not reflected in the plasma concentration of 7αH,3O-CA in mice where we did not observe
a statistical difference between the two genotypes. This can be explained by the existence of an
alternative route to 7αH,3O-CA avoiding CYP7B1 and rather utilizing 7α-hydroxylation of cholesterol
by CYP7A1 [33,41]. The resulting 7α-HC is then oxidized at C-3, before or after oxidation at C-26 by
CYP27A1 to give 7αH,3O-CA.
As mentioned in Section 3.1.2, the level of cholesterol was measured in each of the mouse brains
from both genotypes. Its precursor desmosterol and the 7-DHC isomer 8-DHC are also present in
brain but at much lower levels (see Supplementary Materials, Table S1). The limited dynamic range of
the LC-MS system makes the simultaneous analysis of cholesterol and of its precursors challenging.
As the main focus in this study was on oxysterols and not cholesterol precursors, these sterols were
not investigated thoroughly. Nevertheless, the data from single animals suggest reduced levels of
cholesterol precursors in brain of the Cyp7b1-/- animals. Further studies are required to confirm or
refute this suggestion. Similarly, further studies are required to investigate the concentration in plasma
of 12α-hydroxy metabolites, which in this work were detected but not measured in all animals. Their
presence or absence in brain also requires further investigation.
5. Conclusions
Despite the elimination of a metabolic pathway for cholesterol removal in brain of the Cyp7b1-/-
mouse, the concentration of cholesterol is not elevated. This can be explained by a reduction in its
synthesis due to a down-regulation of the cholesterol biosynthesis pathway by inhibition of SREBP-2
processing by side-chain oxysterols elevated in concentration in brain of the Cyp7b1-/- mouse. Unlike
human CYP7B1-deficiency, the Cyp7b1-/- mouse does not have a pronounced neurological phenotype.
Our results support the view that in mice the production of neurotoxic sterol metabolites is less
marked than in humans, with the consequence that mice do not present with spastic paraplegia, while
humans do.
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